DeuteRx Employee Directory
Biotechnology ResearchNew Hampshire, United States2-10 Employees
DeuteRx has pioneered DECS (deuterium-enabled chiral switching) to create differentiated new chemical entities (NCEs) with new composition of matter patent protection and the potential for an expedited and derisked development path. Our success includes 4 M&A transactions, a Phase 2b NASH drug candidate (PXL065 in collaboration with Poxel SA), surprising discoveries with molecular glue degraders, and >50 issued patents.